Press Release

Morgan Lewis Advises NAMSA in Sale of Majority Interest to ArchiMed

September 02, 2020

WASHINGTON, DC, September 2, 2020: Morgan Lewis represented North American Science Associates Inc. (NAMSA) in its sale of a majority interest to private equity healthcare specialist ArchiMed.

NAMSA is a 100% medical-device-focused, full-continuum contract research organization. NAMSA’s suite of services are designed to lower development costs and accelerate regulatory approval and commercialization globally for medical device and in vitro diagnostics technologies. ArchiMed is an independent investment firm specializing in healthcare with a focus on the biopharma, medtech, diagnostics, life sciences, and healthcare IT sectors.

Partners Tony Chan and Kimberly Taylor, and associates Greer Longer, Kira Schwartz, and Paris Dupree represented NAMSA.

For more, read NAMSA’s announcement.